The study will be conducted exclusively at CTCA at Midwestern Regional Medical Center in suburban Chicago . Eligible participants will be CTCA patients who have stage III or IV ovarian cancer and have tumor progression despite at least one , but no more than two , chemotherapy regimens . Participants in this clinical trial must first receive surgery at CTCA at Midwestern Regional Medical Center and localized chemotherapy infused directly into the abdomen ( intraperitoneal chemotherapy ) , a standard of cancer care available to many CTCA patients . Patients become eligible for the ovarian cancer vaccine trial when it is determined that enough tumor cells can be harvested from the debulked tumor to create the ovarian cancer vaccine and the vaccine has passed rigid quality control testing .